Bone Marrow Aspirate Concentrate With Two-Staged-Revision ACL Reconstruction

Abstract

Background: The incidence of anterior cruciate ligament (ACL) injuries, reconstructions, and re-ruptures has rapidly increased. Patients with failed ACL reconstructions have been reported to suffer from far worse outcomes as compared with those with primary reconstructions, prompting the advancement of surgical and biologic techniques. Effective treatment of re-tears has been shown to be achieved either utilizing a 1-stage or 2-staged approach, with the latter preferred if the patient presents with significant bone loss, previously malpositioned tunnels, or unacceptable tunnel expansion. Recent literature has shown the efficacy of bone marrow aspirate concentrate (BMAC) in improving clinical outcomes and graft integration as well as accelerated ligamentization. Indication: Patients are indicated for surgery when presenting with chronic ACL graft failure and objective insufficiency as well as concerns regarding tunnel overlap, enlargement, or interference. Contraindications for revision involve influences of concurrent injuries that may be secondary causes of the ACL injury. Technique Description: After bone marrow aspiration is performed, the tibial and femoral tunnel apertures are debrided of fibrous tissue with a combination of a shaver and curettes. A threaded guide wire is passed and the interference screws are removed, revealing the residual ruptured graft. A shaver and radiofrequency ablation device are utilized to clean off remaining graft remnants. Sequential debridement and reaming are performed to remove any residual fibrous tissue or sclerotic bone from the tunnel. The demineralized bone matrix is then combined with the prepared BMAC in a syringe with a cannula extension and subsequently injected into the tunnels. A freer elevate is used to tamp and smooth the graft to match the surrounding contour. A 12-mm cannulated allograft bone dowel is then passed up into the tibial tunnel and gently tamped into place. Results: Within 2 years postoperatively, patients are expected to have improved overall knee-specific quality of life, reduced pain, and a successful return to activities. No differences in outcomes have been noted in the literature between 1-staged and 2-staged ACL reconstructions. Discussion/Conclusion: Recent advancements in our understanding of the effects of BMAC in the setting of an ACL reconstruction should prompt surgeons to consider such treatments in indicated patients. Patient Consent Disclosure Statement: The author(s) attests that consent has been obtained from any patient(s) appearing in this publication. If the individual may be identifiable, the author(s) has included a statement of release or other written form of approval from the patient(s) with this submission for publication.